Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.
Introducing the VectraplexECG, the first ECG device to derive a 15-22 lead ECG using only 5-electrodes and CEB® technology to detect a potential heart attack.
VectraCor uses its patented technology to design and develop medical devices to simplify and reduce costs of diagnostic testing as well as improve patient care. Our latest technology, VectraplexECG can detect ECG changes suggestive of a heart attack and derive a 15-22 lead ECG utilizing only 5-electrodes. We have a entire suite of products that are durable, mobile, and ready to turn an off-the-shelf tablet or laptop into a medical device. Our products are FDA cleared, CE marked, and VectraCor is ISO-13485 certified.
Trade Shows 2019
The VectraCor team and CEO Brad Schreck had an excellent time at Medica 2019. If you didn't have time to meet us at our booth and have an inquiry, please feel free to give us a call at 973-904-0444.
Our Product Manager Michael with Dr. Kristian Thygesen of Denmark at the European Society of Cardiology Acute Cardiovascular Care Conference.
750000
People in the U.S have heart attacks each year
116000
People die each year from a heart attack
550000
Have a heart attack for the first time each year
200000
Have recurrent heart attacks
Heart Disease Stroke and Research Statisitcs At-a-Glance by American Heart Association
OUR PRODUCTS
We have a range of products to get you started whether you are an urgent care, primary care, or hospital.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNo
